Similar articles

• [Anti-oestrogen treatment of metastasising carcinoma of the breast (author's transl)].

  Henningsen B, Amberger H. Henningsen B, et al. Dtsch Med Wochenschr. 1977 May 13;102(19):713-6. doi: 10.1055/s-0028-1104958. Dtsch Med Wochenschr. 1977. PMID: 870301 German.
• Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer.

  Han S, Park K, Bae BN, Kim KH, Kim HJ, Kim YD, Kim HY. Han S, et al. Oncol Rep. 2003 Jan-Feb;10(1):141-4. Oncol Rep. 2003. PMID: 12469160
• Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: a Southeastern Cancer Study Group trial.

  Gockerman JP, Spremulli EN, Raney M, Logan T. Gockerman JP, et al. Cancer Treat Rep. 1986 Oct;70(10):1199-203. Cancer Treat Rep. 1986. PMID: 3530447 Clinical Trial.
• The nature of tamoxifen action in the control of female breast cancer.

  Kodama M, Kodama T. Kodama M, et al. In Vivo. 2001 Jul-Aug;15(4):319-25. In Vivo. 2001. PMID: 11695224 Review.
• [Effects and mechanism of action of antiestrogens in breast cancer].

  Borgna JL, Rochefort H. Borgna JL, et al. Sem Hop. 1984 Mar 1;60(10):703-9. Sem Hop. 1984. PMID: 6322320 Review. French.